



Attorney's Docket No. 35800/207197(5800-37A)

#6

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re: Chiang  
Appl. No.: 09/775,009  
Filed: February 1, 2001  
For: NARC8 PROGRAMMED CELL-DEATH ASSOCIATED  
MOLECULES AND USES THEREOF  
Group Art Unit: 1645  
Examiner: Not Assigned

June 11, 2001

Commissioner for Patents  
Washington, DC 20231

**INFORMATION DISCLOSURE STATEMENT  
CITATION UNDER 37 C.F.R. § 1.97**

Sir:

Attached is a list of documents on form PTO-1449 together with a copy of each identified document. It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead submitting the listed documents for the sake of full disclosure.

Respectfully submitted,

*Kathryn L. Coulter*

Kathryn L. Coulter  
Registration No. 45,889

**Customer No. 000826**  
**ALSTON & BIRD LLP**  
Bank of America Plaza  
101 South Tryon Street, Suite 4000  
Charlotte, NC 28280-4000  
Tel Raleigh Office (919) 420-2200  
Fax Raleigh Office (919) 420-2260

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: **Box Missing Parts**, Commissioner For Patents, Washington, DC 20231, on June 11, 2001.

*Nora C. Martinez*  
Nora C. Martinez

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of   

**Complete if Known**

Application Number 09/775,009

Filing Date February 1, 2001

First Named Inventor Chiang

Group Art Unit 1645

Examiner Name Not Assigned

Attorney Docket Number 35800/207197(5800-37A)

### U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant Of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear

### FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Office <sup>3</sup> Number <sup>4</sup>	Kind Code (if known) <sup>5</sup>	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	1	MASUDA <i>et al.</i> , "Nuclear Receptor Binding Factor-1 (NRBF-1), a Protein Interacting with a Wide Spectrum of Nuclear Hormone Receptors," <i>Gene</i> , 1998, pp. 225-233, Vol. 221, No. 2. Gen Bank Accession No. AB015724.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RTA01/2097703v1

<sup>1</sup> Unique citation designation number.

<sup>2</sup> See attached Kinds of U.S. Patent Documents.

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

<sup>6</sup> Applicant is to place an "X" here if English language Translation is attached.